Molecular Pathogenesis of Hepatic Adenomas and Its Implications for Surgical Management

Journal of Gastrointestinal Surgery

Volumn 17, Issue 10, 2013, Pages 1869-1882

  Liau, Siong Seng ^a,b   Qureshi, M Saeed ^a   Praseedom, Raaj ^a   Huguet, Emmanuel ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

Hepatic adenoma; Hepatocellular carcinoma; Malignant transformation; Molecular pathogenesis; Surgery

Indexed keywords

ADENOMA; ARTICLE; CELL TRANSFORMATION; DECISION TREE; GENETICS; GENOTYPE; HUMAN; LIVER TUMOR; PHENOTYPE; RISK FACTOR;

ADENOMA; CELL TRANSFORMATION, NEOPLASTIC; DECISION TREES; GENOTYPE; HUMANS; LIVER NEOPLASMS; PHENOTYPE; RISK FACTORS;

EID: 84884674649     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2274-6     Document Type: Article

References (102)

1. Flejou JF, Barge J, Menu Y, Degott C, Bismuth H, Potet F, Benhamou JP. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985;89(5): 1132-1138.
2. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, Ferrell L, Paradis V, Roskams T, Vilgrain V, Wanless IR, Zucman-Rossi J. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. Journal of hepatology 2007;46(3): 521-527.
3. van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, JN IJ. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006; 93(12): 1495-1502.
4. Ball C, Sackett D, Phillips B, Haynes B, Straus S. Levels of evidence and grades of recommendations. In: EBM (Web site of the Oxford Centre for Evidence-Based Medicine); 2009, http://www. cebm. net/.
5. Jeannot E, Wendum D, Paye F, Mourra N, de Toma C, Flejou JF, Zucman-Rossi J. Hepatocellular adenoma displaying a HNF1alpha inactivation in a patient with familial adenomatous polyposis coli. Journal of Hepatology 2006;45(6): 883-886.
6. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW, Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. Jama 1979;242(7): 644-648.
7. Lee PJ. Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 2002;161 Suppl 1: S46-49.
8. Steinbrecher UP, Lisbona R, Huang SN, Mishkin S. Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 1981;26(11): 1045-1050.
9. Aseni P, Sansalone CV, Sammartino C, Benedetto FD, Carrafiello G, Giacomoni A, Osio C, Vertemati M, Forti D. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001;33(3): 234-236.
10. Ramseur WL, Cooper MR. Asymptomatic liver cell adenomas. Another case of resolution after discontinuation of oral contraceptive use. Jama 1978;239(16): 1647-1648.
11. Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977;86(2): 180-182.
12. Torbenson M, Lee JH, Choti M, Gage W, Abraham SC, Montgomery E, Boitnott J, Wu TT. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol 2002;15(3): 189-196.
13. Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, Chen YT, Kishnani PS. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? Journal of hepatology 2007;46(3): 492-498.
14. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24(3): 276-279.
15. Bannasch P. Sequential cellular changes during chemical carcinogenesis. J Cancer Res Clin Oncol 1984;108(1): 11-22.
16. Bannasch P, Mayer D, Hacker HJ. Hepatocellular glycogenosis and hepatocarcinogenesis. Biochim Biophys Acta 1980;605(2): 217-245.
17. Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P. Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997;26(4): 891-895.
18. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, Sullivan J, Frush DP, Chen YT, Kishnani PS. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis 2005;28(2): 153-162.
19. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 1991;68(2): 341-347.
20. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, Wendum D, Chiche L, Fabre M, Mellottee L, Laurent C, Partensky C, Castaing D, Zafrani ES, Laurent-Puig P, Balabaud C, Bioulac-Sage P. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43(3): 515-524.
21. Micchelli ST, Vivekanandan P, Boitnott JK, Pawlik TM, Choti MA, Torbenson M. Malignant transformation of hepatic adenomas. Mod Pathol 2008;21(4): 491-497.
22. Tao LC. Are oral contraceptive-associated liver cell adenomas premalignant? Acta Cytol 1992;36(3): 338-344.
23. Anthony PP, Vogel CL, Barker LF. Liver cell dysplasia: a premalignant condition. J Clin Pathol 1973;26(3): 217-223.
24. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011;60(1): 85-89.
25. Chiche L, Dao T, Salame E, Galais MP, Bouvard N, Schmutz G, Rousselot P, Bioulac-Sage P, Segol P, Gignoux M. Liver adenomatosis: reappraisal, diagnosis, and surgical management: eight new cases and review of the literature. Ann Surg 2000;231(1): 74-81.
26. Limmer J, Fleig WE, Leupold D, Bittner R, Ditschuneit H, Beger HG. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 1988;8(3): 531-537.
27. Kudo M. Hepatocellular adenoma in type Ia glycogen storage disease. J Gastroenterol 2001;36(1): 65-66.
28. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432(7015): 324-331.
29. Libbrecht L, Desmet V, van Damme B, Roskams T. The immunohistochemical phenotype of dysplastic foci in human liver: correlation with putative progenitor cells. Journal of hepatology 2000;33(1): 76-84.
30. Libbrecht L, De Vos R, Cassiman D, Desmet V, Aerts R, Roskams T. Hepatic progenitor cells in hepatocellular adenomas. The American journal of surgical pathology 2001;25(11): 1388-1396.
31. Deneve JL, Pawlik TM, Cunningham S, Clary B, Reddy S, Scoggins CR, Martin RC, D'Angelica M, Staley CA, Choti MA, Jarnagin WR, Schulick RD, Kooby DA. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009;16(3): 640-648.
32. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB: the official journal of the International Hepato Pancreato Biliary Association 2010;12(8): 509-522.
33. Bioulac-Sage P, Laumonier H, Sa Cunha A, Balabaud C. Hepatocellular adenomas. Liver Int 2009;29(1): 142.
34. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, Balabaud C, Zucman-Rossi J. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007;46(3): 740-748.
35. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular Benign Tumors-From Molecular Classification to Personalized Clinical Care. Gastroenterology 2013.
36. Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, Auffray C, Bioulac-Sage P, Zucman-Rossi J. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 2007;282(19): 14437-14446.
37. van der Borght S, Libbrecht L, Katoonizadeh A, Aerts R, Nevens F, Verslype C, Roskams TA. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 2007;51(6): 855-856.
38. Wilkens L, Bredt M, Flemming P, Becker T, Klempnauer J, Kreipe HH. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol 2001;193(4): 476-482.
39. Nasarek A, Werner M, Nolte M, Klempnauer J, Georgii A. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia. A fluorescence in situ hybridization study. Virchows Arch 1995;427(4): 373-378.
40. Wilkens L, Bredt M, Flemming P, Schwarze Y, Becker T, Mengel M, von Wasielewski R, Klempnauer J, Kreipe H. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn 2001;3(2): 68-73.
41. De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995;10(9): 1725-1729.
42. Macdonald GA, Greenson JK, Saito K, Cherian SP, Appelman HD, Boland CR. Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology 1998;28(1): 90-97.
43. Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, Zucman-Rossi J. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002;32(2): 312-315.
44. Jeannot E, Poussin K, Chiche L, Bacq Y, Sturm N, Scoazec JY, Buffet C, van Nhieu JT, Bellanne-Chantelot C, de Toma C, Laurent-Puig P, Bioulac-Sage P, Zucman-Rossi J. Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res 2007;67(6): 2611-2616.
45. Reznik Y, Dao T, Coutant R, Chiche L, Jeannot E, Clauin S, Rousselot P, Fabre M, Oberti F, Fatome A, Zucman-Rossi J, Bellanne-Chantelot C. Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 2004;89(3): 1476-1480.
46. Bacq Y, Jacquemin E, Balabaud C, Jeannot E, Scotto B, Branchereau S, Laurent C, Bourlier P, Pariente D, de Muret A, Fabre M, Bioulac-Sage P, Zucman-Rossi J. Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology 2003;125(5): 1470-1475.
47. Foster JH, Donohue TA, Berman MM. Familial liver-cell adenomas and diabetes mellitus. N Engl J Med 1978;299(5): 239-241.
48. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384(6608): 455-458.
49. Micsenyi A, Tan X, Sneddon T, Luo JH, Michalopoulos GK, Monga SP. Beta-catenin is temporally regulated during normal liver development. Gastroenterology 2004;126(4): 1134-1146.
50. Monga SP, Monga HK, Tan X, Mule K, Pediaditakis P, Michalopoulos GK. Beta-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 2003;124(1): 202-216.
51. Chen YW, Jeng YM, Yeh SH, Chen PJ. P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36(4 Pt 1): 927-935.
52. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 1998;95(15): 8847-8851.
53. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S, Murata M, Shimano T, Nakamura Y. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998;58(12): 2524-2527.
54. Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155(3): 703-710.
55. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120(7): 1763-1773.
56. Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009;457(7226): 200-204.
57. Bala S, Wunsch PH, Ballhausen WG. Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Gastroenterology 1997;112(3): 919-922.
58. Blaker H, Sutter C, Kadmon M, Otto HF, Von Knebel-Doeberitz M, Gebert J, Helmke BM. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 2004;41(2): 93-98.
59. Tannapfel A, Busse C, Geissler F, Witzigmann H, Hauss J, Wittekind C. INK4a-ARF alterations in liver cell adenoma. Gut 2002;51(2): 253-258.
60. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47(6): 1955-1963.
61. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci U S A 2007;104(37): 14771-14776.
62. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996;84(4): 575-585.
63. Lee YH, Sauer B, Gonzalez FJ. Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse. Mol Cell Biol 1998;18(5): 3059-3068.
64. Flodby P, Liao DZ, Blanck A, Xanthopoulos KG, Hallstrom IP. Expression of the liver-enriched transcription factors C/EBP alpha, C/EBP beta, HNF-1, and HNF-4 in preneoplastic nodules and hepatocellular carcinoma in rat liver. Mol Carcinog 1995;12(2): 103-109.
65. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Guidelines for management of glycogen storage disease type I-European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161 Suppl 1: S112-119.
66. Lee SH, Hahn ST. Treatment of multiple hepatic adenomatosis using transarterial chemoembolization: a case report. Cardiovasc Intervent Radiol 2004;27(5): 563-565.
67. Akovbiantz A, Ackermann D, Buhler H, Schmid M. [Management of liver cell adenoma and focal nodular hyperplasia]. Helv Chir Acta 1980;47(5): 607-609.
68. Monga SP. Hepatic adenomas: presumed innocent until proven to be beta-catenin mutated. Hepatology 2006;43(3): 401-404.
69. Davis M, Portmann B, Searle M, Wright R, Williams R. Histological evidence of carcinoma in a hepatic tumor associated with oral contraceptives. Br Med J 1975;4(5995): 496-498.
70. Pryor AC, Cohen RJ, Goldman RL. Hepatocellular carcinoma in a woman on long-term oral contraceptives. Cancer 1977;40(2): 884-888.
71. Tesluk H, Lawrie J. Hepatocellular adenoma. Its transformation to carcinoma in a user of oral contraceptives. Arch Pathol Lab Med 1981;105(6): 296-299.
72. Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986;105(4): 547-549.
73. Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med 1989;110(6): 489-490.
74. Korula J, Yellin A, Kanel G, Campofiori G, Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J Med 1991;155(4): 416-418.
75. Ferrell LD. Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. The American journal of surgical pathology 1993;17(5): 525-529.
76. Janes CH, McGill DB, Ludwig J, Krom RA. Liver cell adenoma at the age of 3 years and transplantation 19 years later after development of carcinoma: a case report. Hepatology 1993;17(4): 583-585.
77. Perret AG, Mosnier JF, Porcheron J, Cuilleron M, Berthoux P, Boucheron S, Audigier JC. Role of oral contraceptives in the growth of a multilobular adenoma associated with a hepatocellular carcinoma in a young woman. Journal of hepatology 1996;25(6): 976-979.
78. Ye MQ, Suriawinata A, Ben Haim M, Parsons R, Schwartz ME. A 42-year-old woman with liver masses and long-term use of oral contraceptives. Semin Liver Dis 1999;19(3): 339-344.
79. Burri E, Steuerwald M, Cathomas G, Mentha G, Majno P, Rubbia-Brandt L, Meier R. Hepatocellular carcinoma in a liver-cell adenoma within a non-cirrhotic liver. European journal of gastroenterology & hepatology 2006;18(4): 437-441.
80. Colovic R, Grubor N, Micev M, Radak V. Hepatocellular adenoma with malignant alteration. Hepatogastroenterology 2007;54(74): 386-388.
81. Kim DH, Kim SU, Nam DH, Choi YJ, Park SM, Lee CK, Kim do Y. A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. The Korean journal of internal medicine 2009;24(2): 147-152.
82. Toiyama Y, Inoue Y, Yasuda H, Yoshiyama S, Araki T, Miki C, Kusunoki M. Hepatocellular adenoma containing hepatocellular carcinoma in a male patient with familial adenomatous polyposis coli: Report of a case. Surgery today 2011;41(10): 1442-1446.
83. Hechtman JF, Raoufi M, Fiel MI, Taouli B, Facciuto M, Schiano TD, Blouin AG, Thung SN. Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear beta-catenin and glutamine synthetase positivity: case report and review of the literature. The American journal of surgical pathology 2011;35(6): 927-932.
84. Lack EE, Neave C, Vawter GF. Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer 1983;52(8): 1510-1515.
85. Kerlin P, Davis GL, McGill DB, Weiland LH, Adson MA, Sheedy PF, 2nd. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983;84(5 Pt 1): 994-1002.
86. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988;208(5): 558-564.
87. Belghiti J, Pateron D, Panis Y, Vilgrain V, Flejou JF, Benhamou JP, Fekete F. Resection of presumed benign liver tumours. Br J Surg 1993;80(3): 380-383.
88. Herman P, Machado MA, Volpe P, Pugliese V, Vianna MR, Bacchella T, Machado MC, Pinotti HW. [Transformation of hepatic adenoma into hepatocellular carcinoma in patients with prolonged use of oral contraceptives]. Rev Hosp Clin Fac Med Sao Paulo 1994;49(1): 30-33.
89. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994;129(7): 712-717.
90. Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World journal of surgery 1995;19(1): 13-18.
91. Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC. Selective management of hepatic adenomas. Am Surg 1996;62(10): 825-829.
92. De Carlis L, Pirotta V, Rondinara GF, Sansalone CV, Colella G, Maione G, Slim AO, Rampoldi A, Cazzulani A, Belli L, Forti D. Hepatic adenoma and focal nodular hyperplasia: diagnosis and criteria for treatment. Liver Transpl Surg 1997;3(2): 160-165.
93. Weimann A, Ringe B, Klempnauer J, Lamesch P, Gratz KF, Prokop M, Maschek H, Tusch G, Pichlmayr R. Benign liver tumors: differential diagnosis and indications for surgery. World journal of surgery 1997;21(9): 983-990; discussion 990-981.
94. Closset J, Veys I, Peny MO, Braude P, van Gansbeke D, Lambilliotte JP, Gelin M. Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 2000;47(35): 1382-1384.
95. Ichikawa T, Federle MP, Grazioli L, Nalesnik M. Hepatocellular adenoma: multiphasic CT and histopathologic findings in 25 patients. Radiology 2000;214(3): 861-868.
96. Reddy KR, Kligerman S, Levi J, Livingstone A, Molina E, Franceschi D, Badalamenti S, Jeffers L, Tzakis A, Schiff ER. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001;67(2): 173-178.
97. Charny CK, Jarnagin WR, Schwartz LH, Frommeyer HS, DeMatteo RP, Fong Y, Blumgart LH. Management of 155 patients with benign liver tumours. Br J Surg 2001;88(6): 808-813.
98. Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumours. Digestive surgery 2002;19(2): 109-113.
99. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, Bedossa P, Belghiti J. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009;137(5): 1698-1705.
100. Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. Characterization of hepatocellular adenoma based on the phenotypic classification: The Kanazawa experience. Hepatology research: the official journal of the Japan Society of Hepatology 2011;41(10): 982-988.
101. Bellamy CO, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre. Histopathology 2013;62(3): 431-445.
102. Fonseca S, Hoton D, Dardenne S, Annet L, Hubert C, Godecharles S, Jouret-Mourin A, Reding R, Otte JB, Rahier J, Gigot JF, Sempoux C. Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. International journal of hepatology 2013;2013: 398308.